Keytruda may offer new hope for cervical precancer
NCT ID NCT04712851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can treat high-grade cervical precancer (CIN 2/3 or carcinoma in situ). The study will enroll 25 women and measure how many have a complete response at 6 months. The goal is to see if this drug can help the immune system clear abnormal cells without surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda)
What this could lead to
If successful, this could offer a non-surgical treatment option for high-grade cervical precancer, potentially reducing the need for surgery.
What could go wrong
This is a small, early-phase trial with only 25 participants. The drug may not work for everyone, and side effects from immunotherapy can occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California at Los Angeles / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••